Oral mucositis associated with anti-egfr therapy in colorectal cancer: single institutional retrospective cohort study.

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: DOTE, Satoshi (Kyoto-Katsura Hospital, Department of pharamcy, Kyoto, Japan)
  • Co-author(s): Satoshi Dote: Department of pharamcy, Kyoto-Katsura Hospital, Kyoto, Japan;Department of pharamcy, Shiga University of Medical Science Hospital, Shiga, Japan
    Shoji Itakura: Department of pharamcy, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan
    Daiki Hira: Department of pharamcy, Shiga University of Medical Science Hospital, Shiga, Japan
    Satoshi Noda: Department of pharamcy, Shiga University of Medical Science Hospital, Shiga, Japan
    Yuka Kobayashi: Department of pharamcy, Kyoto-Katsura Hospital, Kyoto, Japan
    Tomohiro Terada: Department of pharamcy, Shiga University of Medical Science Hospital, Shiga, Japan
  • Abstract:

    Methods

    We conducted a retrospective cohort study. A total of 75 colorectal cancer outpatients treated with anti-EGFR therapy combined with FOLFOX, FOLFIRI, or 5FU/LV as first to third line setting at Kyoto-Katsura Hospital between January, 2012, and March, 2017 were included. Primary endpoint was the incidence of grade 2-3 oral mucositis. The..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login